Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke | Synapse

February 19, 2024Open Access

Ver artículo completo

Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke

YFYu FuFujian Medical University AWAnxin WangPreventive Cardiology RTRenhong TangNational Medical Products Administration

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sublingual edaravone dexborneol, which can rapidly diffuse and be absorbed through the oral mucosa after sublingual exposure, is a multitarget brain cytoprotection composed of antioxidant and anti-inflammatory ingredients edaravone and dexborneol.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Fu et al. (Mon,) studied this question.

synapsesocial.com/papers/68e78822b6db6435876fb029 https://doi.org/https://doi.org/10.1001/jamaneurol.2023.5716

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial2023 · 5 citations
2Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 20102012 · 113 citations
3Protection by borneol on cortical neurons against oxygen-glucose deprivation/reperfusion: involvement of anti-oxidation and anti-inflammation through nuclear transcription factor κappaB signaling pathway2010 · 183 citations
4Untitled2012 · 1 citations
5A new formulation for orally disintegrating tablets using a suspension spray-coating method2009 · 65 citations